Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

CONCLUSIONS: A large proportion of high-intensity, statin-treated, high-risk patients with ASCVD and of self-reported SA ethnicity are eligible for IPE. These data have important translational implications for SAs who are at a disproportionately higher risk of CV morbidity and mortality.FUNDING: This study was funded by an unrestricted grant provided by HLS Therapeutics Inc, Canada.PMID:36630964 | DOI:10.1016/j.medj.2022.12.008

Source: Atherosclerosis - January 11, 2023 Category: Cardiology Authors: Aishwarya Krishnaraj Ehab Bakbak Hwee Teoh Deepak L Bhatt Adrian Quan Pankaj Puar Bhaavani Lambotharan Aathmika Kirubaharan Irene N Firoz Gus Meglis Bobby Yanagawa Basel Bari Rajaratnam Kirubaharan Ram Vijayaraghavan David A Hess Andrew M Demchuk G B John Source Type: research